Gamida Cell (GMDAQ) Stock Price
Gamida Cell Price
Gamida Cell (GMDAQ) Stock | ISIN IL0011552663 | WKN A2N7XM. The current Gamida Cell stock price is 0.02 USD (2026). Market capitalization is 1.87 M USD. Gamida Cell operates in the Health sector.
Gamida Cell stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Gamida Cell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Gamida Cell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Gamida Cell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Gamida Cell Price |
|---|
Gamida Cell Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Gamida Cell Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Gamida Cell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Gamida Cell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Gamida Cell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Gamida Cell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Gamida Cell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Gamida Cell stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Gamida Cell Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Gamida Cell business model & stock analysis
Gamida Cell SWOT Analysis
Strengths
1. Innovative Technology: Gamida Cell Ltd is known for its cutting-edge technology in cell therapy, which provides a competitive advantage in the market.
2. Strong Research and Development: The company has a robust R&D department that constantly strives to develop new and improved treatments, enhancing its product portfolio.
3. Strategic Partnerships: Gamida Cell maintains collaborations with key industry players, allowing access to additional resources, expertise, and potential distribution channels.
Weaknesses
1. Limited Market Presence: Despite its innovative technology, Gamida Cell faces challenges in establishing a strong market presence due to intense competition and regulatory barriers.
2. Financial Dependency: The company heavily relies on external funding to support its operations, which can pose risks during economic downturns or fluctuating investor confidence.
3. Scale and Production Capacity: Gamida Cell's limited scale and production capacity could potentially hinder its ability to meet market demand effectively, delaying growth opportunities.
Opportunities
1. Expanding Cell Therapy Market: With the increasing demand for advanced medical treatments, Gamida Cell has the opportunity to capitalize on the growing cell therapy market.
2. Regulatory Advancements: Regulatory bodies worldwide are becoming more supportive of cell therapy, creating favorable conditions for Gamida Cell to obtain necessary approvals with relative ease.
3. Strategic Partnerships: Collaborating with pharmaceutical companies or research institutions could enable Gamida Cell to broaden its product pipeline and access new markets or patient populations.
Threats
1. Competitive Landscape: Gamida Cell operates in a highly competitive industry with numerous established players vying for market share, intensifying the threat of competition.
2. Regulatory Challenges: The evolving and stringent regulatory frameworks governing cell therapy can result in delays or increased costs associated with gaining necessary approvals for Gamida Cell's products.
3. Technological Advancements: Competitors' advancements in cell therapy or alternative medical treatment options could potentially render Gamida Cell's technology outdated or less attractive to customers.
Gamida Cell Eulerpool Fair Value
Gamida Cell historical P/E ratio, EBIT multiple, and P/S ratio
Gamida Cell annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Gamida Cell shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Gamida Cell shareholder structure
| % | Name |
|---|---|
6.91924% | |
4.6974% | |
3.94073% | |
3.4054% | |
3.32137% | |
2.34598% | |
2.33428% | |
2.00999% | |
1.25228% | |
0.92973% |
Gamida Cell Executives and Management Board
Dr. Julian Adams
(68)Director · since 2016
Dr. Ronit Simantov
(58)Chief Medical Officer
Mr. Joshua Hamermesh
(48)Chief Business Officer
Dr. Jas Uppal
(53)Chief Regulatory, Quality Officer
Ms. Shawn Tomasello
(64)Independent Non-Executive Chairwoman of the Board
Frequently asked questions about Gamida Cell
The business model of Gamida Cell Ltd focuses on the development and commercialization of innovative cell therapies to treat and cure cancer and rare genetic diseases. Gamida Cell utilizes its proprietary technology platform, NiCord®, to expand umbilical cord blood cells and create therapies that can be readily available for patients in need. By partnering with industry leaders and conducting clinical trials, Gamida Cell aims to deliver effective and accessible treatments to improve the lives of patients worldwide. As a leading biotechnology company, Gamida Cell is committed to advancing the field of cell therapy and bringing hope to patients and their families.
Gamida Cell stock
Gamida Cell Peer Group
Gamida Cell Ticker
Gamida Cell FIGI
All fundamentals and in-depth analysis of Gamida Cell
Our stock analysis for Gamida Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gamida Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.